A monthly update for cardiac and vascular professionals.

Please visit our sponsor below to keep CathLab.com a free resource.

Win **FREE** registration to **TCT Nurse and Tech Symposium**.
Like us on Facebook for your chance to win!

Pennsylvania College of Health Sciences is now accepting applications for the **Online Professional Certificate in Cardiac Electrophysiology**. Classes begin August 20, 2018.

For admissions and application information for the Professional Certificate [click here](#). To talk to an admissions counselor, [click here](#).

Apply today. Use the promotional code **CLDC2018** and the **application fee** will be waived. Offer expires July 31, 2018.

**FEATURED APPLICATION**

**CardioSmart Heart Explorer**
The CardioSmart Heart Explorer app for iOS (iPhone/iPad) and Android is designed to enhance the clinician-patient relationship at the point of care. By using the app’s high-resolution cardiac graphics and animations, clinicians can effectively review and discuss common heart problems and treatment options.

**FEATURED JOBS**
NEWSSTAND EDITOR'S PICKS

**Lack of health literacy ‘major barrier’ in CVD prevention, treatment**
A new scientific statement issued by the American Heart Association (AHA) suggests limited health literacy is a major barrier that blocks many people from achieving good cardiovascular health or benefitting from effective treatment for myocardial infarction, heart failure, stroke and other cardiovascular diseases.

**Cardiology Societies Call for Better Radiation Dose Tracking**
A new consensus document on how to mitigate radiation exposure in cardiac imaging for both patients and staff was issued in May, and it advocates for greater use of radiation dose monitoring technologies.

**Ticagrelor Doesn’t Carry Any Off-Target Effects Compared With Clopidogrel, Prasugrel**
New randomized data are crossing out a long-held hypothesis many assumed about how the potent antiplatelet agent ticagrelor works. Contrary to expectations, the drug does not appear to convey any additional off-target effects related to endothelial function or increased systemic adenosine plasma levels compared with prasugrel and clopidogrel in stable patients following an ACS.
The United States Food and Drug Administration (FDA) has classified Medtronic plc’s (NYSE: MDT) recent voluntary urgent field action related to the HeartWare(TM) HVAD(TM) System unexpected power source switching as a Class I recall.

Abbott today announced real-world results that showed treatment with the company’s AMPLATZER™ Amulet™ left atrial appendage (LAA) occlusion device in patients with irregular heart beats, known as atrial fibrillation (AF), reduced the risk of stroke, transient ischemic attack (TIA) and systemic embolism (SE) without the need for blood-thinning medication.

Medtronic announced study results showing its exclusive AdaptivCRT(TM) algorithm is associated with improved patient survival. The data were recently presented at Heart Rhythm 2018, the Heart Rhythm Society’s 39th Annual Scientific Sessions in Boston.

TCT 2018
Date: 09/21/2018 - 09/25/2018
City/State: San Diego, CA
Venue: San Diego Convention Center

15th Annual Meeting of the ESC Working Group on Myocardial and Pericardial Diseases
Date: 10/05/2018 - 10/07/2018
City/State: Belgrade, Serbia

AHA 2018
Date: 11/10/2018 - 11/14/2018
City/State: Chicago, IL
Venue: McCormick Place Convention Center